Domov › Mikrocitni rak pljuč › Tennessee › Nashville
Klinične študije za Mikrocitni rak pljuč v Nashville, TN
20 študij za Mikrocitni rak pljuč išče udeležence na lokacijah v Nashville in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI), Nashville
DESTINY-PANTUMOUR04
Vključevanje udeležencevOpazovalna študija
- Research Site, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Vključevanje udeležencevFaza 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon - Tennessee Oncology, Nashville
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Vključevanje udeležencevFaza 1/2
- SCRI Oncology Partners, Nashville
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Vključevanje udeležencevFaza 3
- SCRI OP (Oncology Partners), Nashville
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Vključevanje udeležencevFaza 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute ( Site 7001), Nashville
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- SCRI Oncology Partners, Nashville
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- SCRI Oncology Partners, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- Tennessee Oncology, PLLC, Nashville
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Vključevanje udeležencevFaza 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
Vključevanje udeležencevFaza 1
- Sarah Cannon Research Institute, Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site 136, Nashville
Študije za Mikrocitni rak pljuč v drugih mestih
- Houston, TX26 študij
- Arlington, VA23 študij
- New York City, NY22 študij
- Boston, MA21 študij
- Los Angeles, CA20 študij
- Orlando, FL15 študij
- Dallas, TX13 študij
- Cleveland, OH13 študij
- Chicago, IL13 študij
- St. Louis, MO13 študij
- Detroit, MI12 študij
- Washington, DC12 študij
Druge študije v Nashville
- Nemalicelični pljučni rak97 študij
- Rak dojke81 študij
- Metastatski rak70 študij
- Kolorektalni rak69 študij
- Rak (vse vrste)65 študij
- Rak jajčnikov49 študij
- Rak prostate43 študij
- Rak pljuč40 študij
- Ploščatocelični karcinom glave in vratu39 študij
- Rak trebušne slinavke39 študij
- Rak endometrija38 študij
- Melanom33 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.